A new study carried out by France\u2019s Pasteur Institute’s suggested that the Pfizer vaccine is slightly less effective but still protect against the more transmissible Covid variant emerged in India.<\/p>\n\n\n\n
Olivier Schwartz, the institute\u2019s director and co-author of the study published on the BioRxiv website ahead of peer review, said despite slightly diminished efficacy, the Pfizer vaccine probably protects against the variant found in India. These outcomes have been outlined on the basis laboratory test.<\/p>\n\n\n\n
The study sampled 28 healthcare workers in the city of Orleans. Sixteen of them had received two doses of the Pfizer vaccine, while 12 had received one dose of the AstraZeneca vaccine.<\/p>\n\n\n\n
As per the study people who had received two doses of Pfizer vaccine saw a three-fold reduction in their antibodies against the Indian variant but were still protected. The situation was different with the AstraZeneca vaccine, which induced particularly low levels of antibodies neutralizing the variant.<\/p>\n\n\n\n
Schwartz said the study shows that this variant has acquired partial resistance to antibodies. Since first emerging in late 2019 in China, the SARS-CoV-2 virus that causes Covid-19 has developed several variants, usually named for the places where it first appeared including the so-called South Africa and UK strains.<\/p>\n\n\n\n
The variant first detected in India appears to be much more transmissible than earlier variations and it has now been officially recorded in 53 territories. France and Germany have re-introduced tighter rules on arrivals from affected countries, including the United Kingdom to curb its spread.<\/p>\n\n\n\n